Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment
Authors' conclusion
In this matched cohort study, MBS was associated with lower risk for MACE compared to treatment with early GLP-1 RA in patients with T2D.
Study context
- Population
- Patients with T2D and severe obesity, Sweden 2007–2019; Metabolic and bariatric surgery (MBS): obesity class I 10.2%, II 40.3%, III 49.5%; mean age 51.1 vs 51.5 years, 64.8% vs 64.4% womenmatched cohort
- Participants
- 2,161 vs 2,161
- Exposure
- MBS vs GLP-1 RA treatment
- MBSn = 2,161
- GLP-1 RAn = 2,161reference
- Outcome
- MACE (hospitalization for acute coronary syndrome or cerebrovascular event or all-cause death), multivariable Cox regression
Methodological detailsnationwide
- Nationwide
Main finding
As reported in the abstract
MACE or all-cause mortality · 8-year cumulative incidence
Non-surgical patients with MACE or all-cause mortality (8-year cumulative incidence 11.3%)
130
HR for MACE or all-cause mortality
0.76
95%CI 0.59–0.98
Observational data: associations, not effects.
Further findings
- Non-surgical patients with non-fatal MACE (8-year cumulative incidence 7.6%)
- 92
- HR for non-fatal MACE
- 0.68 (95%CI 0.49-0.93)
Original publication
Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. Int J Obes (Lond). Published 20 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →